Form 4: Seres Therapeutics Director Acquires Stock Options
Statement of Changes in Beneficial Ownership
Director Dennis A. Ausiello of Seres Therapeutics, Inc. acquired 6,500 stock options on July 8, 2026, as detailed in a Form 4 filing.
Summary
- Director Dennis A. Ausiello acquired 6,500 stock options in Seres Therapeutics, Inc. on July 8, 2026.
- The stock options have an exercise price of $7.14 and an expiration date of July 7, 2036.
- These options vest and become exercisable on the earlier of July 8, 2027, or the day before the first annual stockholder meeting after July 8, 2026.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard grant of stock options to a director, which is a common compensation practice and does not inherently indicate positive or negative company performance.
Positives
- Director acquisition of stock options can signal confidence in the company's future prospects.
- The acquisition of 6,500 options provides the director with potential upside in the company's stock.
Risks
- The value of the stock options is contingent on the future performance of Seres Therapeutics' stock price.
- There is a risk that the stock price may not appreciate sufficiently to make the options profitable by their expiration date.
Future Outlook
The future outlook for the stock options is dependent on the company's stock performance, with vesting contingent on specific future dates and events.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into executive and director compensation and potential confidence signals.
Stakeholder Impact
- Shareholders: The grant of options to a director is a standard compensation practice. The potential exercise of these options could lead to dilution if new shares are issued, or it could indicate insider confidence if the director exercises them when the stock price is favorable.
Next Steps
- The stock options will vest and become exercisable on the earlier of July 8, 2027, or the day immediately prior to the first annual meeting of the Company's stockholders occurring after July 8, 2026.
- The director may exercise these options at any time after they become vested and before the expiration date of July 7, 2036.
Key Dates
| Date | Description |
|---|---|
| 07/08/2026 | Earliest transaction date and date of stock option acquisition. |
| 07/07/2036 | Expiration date of the acquired stock options. |
| 07/08/2027 | Vesting date for the stock options (earlier of this date or day prior to first annual meeting after 07/08/2026). |
| 07/10/2026 | Date of signature for the Form 4 filing. |
Keywords
Seres Therapeutics, MCRB, Form 4, Stock Options, Director, Beneficial Ownership, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.